The Rheumatologist
COVID-19 News
  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed
  • Home
  • Conditions
    • Rheumatoid Arthritis
    • SLE (Lupus)
    • Crystal Arthritis
      • Gout Resource Center
    • Spondyloarthritis
    • Osteoarthritis
    • Soft Tissue Pain
    • Scleroderma
    • Vasculitis
    • Systemic Inflammatory Syndromes
    • Guidelines
  • Resource Centers
    • Axial Spondyloarthritis Resource Center
    • Gout Resource Center
    • Psoriatic Arthritis Resource Center
    • Rheumatoid Arthritis Resource Center
    • Systemic Lupus Erythematosus Resource Center
  • Drug Updates
    • Biologics & Biosimilars
    • DMARDs & Immunosuppressives
    • Topical Drugs
    • Analgesics
    • Safety
    • Pharma Co. News
  • Professional Topics
    • Ethics
    • Legal
    • Legislation & Advocacy
    • Career Development
      • Certification
      • Education & Training
    • Awards
    • Profiles
    • President’s Perspective
    • Rheuminations
    • Interprofessional Perspective
  • Practice Management
    • Billing/Coding
    • Quality Assurance/Improvement
    • Workforce
    • Facility
    • Patient Perspective
    • Electronic Health Records
    • Apps
    • Information Technology
    • From the College
    • Multimedia
      • Audio
      • Video
  • Resources
    • Issue Archives
    • ACR Convergence
      • Systemic Lupus Erythematosus Resource Center
      • Rheumatoid Arthritis Resource Center
      • Gout Resource Center
      • Abstracts
      • Meeting Reports
      • ACR Convergence Home
    • American College of Rheumatology
    • ACR ExamRheum
    • Research Reviews
    • ACR Journals
      • Arthritis & Rheumatology
      • Arthritis Care & Research
      • ACR Open Rheumatology
    • Rheumatology Image Library
    • Treatment Guidelines
    • Rheumatology Research Foundation
    • Events
  • About Us
    • Mission/Vision
    • Meet the Authors
    • Meet the Editors
    • Contribute to The Rheumatologist
    • Subscription
    • Contact
  • Advertise
  • Search
You are here: Home / Articles / Higher Fracture Risk in Patients with Polymyalgia Rheumatica, Giant-Cell Arteritis

Higher Fracture Risk in Patients with Polymyalgia Rheumatica, Giant-Cell Arteritis

January 24, 2018 • By Will Boggs MD

  • Tweet
  • Email
Print-Friendly Version / Save PDF

NEW YORK (Reuters Health)—Patients with polymyalgia rheumatica (PMR) and giant-cell arteritis (GCA) have similarly increased risks of fracture, compared with the general population, researchers have found.

You Might Also Like
  • How to Manage Patients with Giant Cell Arteritis and Polymyalgia Rheumatica
  • Letters: More on the History of Polymyalgia Rheumatica and Giant Cell Arteritis
  • Two Inflammatory Conditions—Polymyalgia Rheumatica and Giant Cell Arteritis—Share Clinical Connection
Also By This Author
  • Brain Connectivity Predicts Placebo Response in Chronic Pain Patients

“It is of surprise that patients with GCA have a similar fracture risk to those with PMR,” Dr. Zoe Paskins from Keele University, in Staffordshire, told Reuters Health by email. “I would expect it to be higher, as GCA is typically treated with twice the cumulative dose of steroid over the course of the condition. One explanation for this is that PMR is overtreated, and the real-life doses of steroids used in PMR needs further evaluation.”

ad goes here:advert-1
ADVERTISEMENT
SCROLL TO CONTINUE

GCA and PMR, which overlap in many patients, are typically treated with glucocorticoids, which are a well-established cause of osteoporosis and fragility fracture.

Dr. Paskins’s team used data from the UK’s Clinical Practice Research Datalink database to quantify separately the risks of fracture among patients with PMR and GCA and to assess the impact of age, sex, glucocorticoids and methotrexate on those risks.

ad goes here:advert-2
ADVERTISEMENT
SCROLL TO CONTINUE

Their retrospective study included 12,136 PMR and 2,673 GCA patients (735 patients had both conditions), matched to 46,238 and 10,423 nonexposed patients (controls), respectively.

Compared with their separate control populations, the risk of fracture was 63% higher in patients with PMR (148 fractures per 10,000 person-years) and 67% higher in patients with GCA (147 fractures per 10,000 person-years), both significant increases, the team reports in BMC Medicine, online January 10.

The risks were similar for both sexes, and the relative risks were even higher among individuals age 50 to 60 (2.23-fold higher for PMR and 2.27-fold higher for GCA, compared with their respective controls).

ad goes here:advert-3
ADVERTISEMENT
SCROLL TO CONTINUE

The fracture risk was increased at all sites in PMR patients, whereas GCA patients had an increased risk of wrist, vertebral and hip fractures, but not of humeral fractures.

Higher doses of glucocorticoids were associated with higher fracture risks, whereas methotrexate prescription was not associated with the risk of fracture in either group.

Even among GCA and PMR patients with at least two prescriptions for glucocorticoids, only 12.6% and 10.1%, respectively, were prescribed bisphosphonates.

“In view of the increased fracture risk in both conditions, the results highlight the importance of using bone protection in these patients, and assessing and managing falls risk,” Dr. Paskins said.

The researchers say “more research is needed into optimal glucocorticoid tapering regimes to identify whether lower starting doses and/or aggressive dose reduction reduces fracture risk, particularly in PMR, and to explore the safety and benefit of using non-glucocorticoid treatments and glucocorticoid sparing agents in the treatment of these conditions.”

Pages: 1 2 | Single Page

Filed Under: Conditions, Vasculitis Tagged With: fracture risk, Fractures, giant cell arteritis (GCA), polymyalgia rheumatica (PMR)

You Might Also Like:
  • How to Manage Patients with Giant Cell Arteritis and Polymyalgia Rheumatica
  • Letters: More on the History of Polymyalgia Rheumatica and Giant Cell Arteritis
  • Two Inflammatory Conditions—Polymyalgia Rheumatica and Giant Cell Arteritis—Share Clinical Connection
  • Permanent Vision Loss in Late Giant Cell Arteritis

ACR Convergence

Don’t miss rheumatology’s premier scientific meeting for anyone involved in research or the delivery of rheumatologic care or services.

Visit the ACR Convergence site »

Rheumatology Research Foundation

The Foundation is the largest private funding source for rheumatology research and training in the U.S.

Learn more »

Meeting Abstracts

Browse and search abstracts from the ACR Convergence and ACR/ARP Annual Meetings going back to 2012.

Visit the Abstracts site »

The Rheumatologist newsmagazine reports on issues and trends in the management and treatment of rheumatic diseases. The Rheumatologist reaches 11,500 rheumatologists, internists, orthopedic surgeons, nurse practitioners, physician assistants, nurses, and other healthcare professionals who practice, research, or teach in the field of rheumatology.

About Us / Contact Us / Advertise / Privacy Policy / Terms of Use

  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed

Copyright © 2006–2022 American College of Rheumatology. All rights reserved.

ISSN 1931-3268 (print)
ISSN 1931-3209 (online)